Inhibrx Biosciences, Inc. (INBX) stock
INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$74.18−3.48 (-4.48%)
Close on Nov 17, 2026Market cap $1.09BP/E –Yield –
Inhibrx Biosciences operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Inhibrx Biosciences's operating cash flow for the twelve months ending Sep 30, 2026 was -$132.67M. For fiscal 2025 it was -$129.79M. The highest annual figure on record is -$32.08M in fiscal 2019.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$129.79M | – |
| FY2024 | Dec 31, 2024 | -$194.41M | – |
| FY2023 | Dec 31, 2023 | -$193.31M | – |
| FY2022 | Dec 31, 2022 | -$115.30M | – |
| FY2021 | Dec 31, 2021 | -$80.32M | – |
| FY2020 | Dec 31, 2020 | -$47.97M | – |
| FY2019 | Dec 31, 2019 | -$32.08M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$34.61M | – |
| Q2 FY2026 | Jun 30, 2026 | -$29.92M | – |
| Q1 FY2026 | Mar 31, 2026 | -$38.03M | – |
| Q4 FY2025 | Dec 31, 2025 | -$30.12M | – |
| Q3 FY2025 | Sep 30, 2025 | -$33.82M | – |
| Q2 FY2025 | Jun 30, 2025 | -$29.95M | – |
| Q1 FY2025 | Mar 31, 2025 | -$35.90M | – |
| Q4 FY2024 | Dec 31, 2024 | -$43.72M | – |
| Q3 FY2024 | Sep 30, 2024 | -$30.28M | – |
| Q2 FY2024 | Jun 30, 2024 | -$57.36M | – |
| Q1 FY2024 | Mar 31, 2024 | -$63.05M | – |
| Q4 FY2023 | Dec 31, 2023 | -$56.82M | – |
| Q3 FY2023 | Sep 30, 2023 | -$54.25M | – |
| Q2 FY2023 | Jun 30, 2023 | -$42.30M | – |
| Q1 FY2023 | Mar 31, 2023 | -$39.94M | – |
| Q4 FY2022 | Dec 31, 2022 | -$30.60M | – |
| Q3 FY2022 | Sep 30, 2022 | -$30.84M | – |
| Q2 FY2022 | Jun 30, 2022 | -$26.92M | – |
| Q1 FY2022 | Mar 31, 2022 | -$26.94M | – |
| Q4 FY2021 | Dec 31, 2021 | -$22.62M | – |
| Q3 FY2021 | Sep 30, 2021 | -$13.68M | – |
| Q2 FY2021 | Jun 30, 2021 | -$22.38M | – |
| Q1 FY2021 | Mar 31, 2021 | -$21.65M | – |
| Q4 FY2020 | Dec 31, 2020 | -$15.39M | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.88M | – |
| Q2 FY2020 | Jun 30, 2020 | -$11.31M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.39M | – |
| Q4 FY2019 | Dec 31, 2019 | -$11.94M | – |
See a number that looks wrong?